About PPTA

The Plasma Protein Therapeutics Association (PPTA) is a dynamic trade association that represents a unique sector of the biologics and biotechnology industry. PPTA represents more than 1,000 human plasma collection centers in North America and Europe, as well as the manufacturers of lifesaving plasma protein therapies. Our members produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.

The Plasma Protein Therapeutics Association (PPTA) represents the manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions.

PPTA works globally to:

  • Advocate for access to and affordability of therapies for patients

  • Engage in constructive dialogue with regulatory agencies

  • Collaborate with patient advocacy organizations


PPTA also administers standards and programs that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients.


Plasma Collection & Availability of Plasma Products in Europe and the U.S.

  • Each year, millions of plasma donations are made across Europe and the United States at IQPP certified centers. View annual donation totals for Europe and the U.S.

  • Information about the aggregated distribution of plasma protein therapies in the U.S. is provided through PPTA’s North America Distribution Data Program, available here.

  • Collaborate with patient advocacy organizations

Read more

What we do

We work globally to advocate for patient access to plasma-derived medicines, responsibly improve the availability of plasma, and advance the understanding of the plasma ecosystem.

Our association administers standards programs that help to ensure the quality and safety of plasma collection and manufacturing, as well as protect both donors and patients.

See all advocacy material

Mission

Code of ethics

Adhering to the PPTA Code of Ethics

Foster

Fostering the collection of high-quality plasma from healthy donors

Educate

Educating all stakeholders about the value of the therapies

Reimbursment

Supporting government reimbursement practices that reflect the unique nature of plasma protein therapies;

Barriers breaker

Breaking down artificial barriers on trade and compensated donors that limit patient access to therapy

Safety & quality

Establishing standards for the manufacturing of lifesaving plasma protein therapies at the highest levels of safety and quality

Mission

Foster

Fostering the collection of high-quality plasma from healthy donors

Safety & quality

Establishing standards for the manufacturing of lifesaving plasma protein therapies at the highest levels of safety and quality

Reimbursment

Supporting government reimbursement practices that reflect the unique nature of plasma protein therapies;

Educate

Educating all stakeholders about the value of the therapies

Code of ethics

Adhering to the PPTA Code of Ethics

Barriers breaker

Breaking down artificial barriers on trade and compensated donors that limit patient access to therapy

European Plasma Alliance

Who we are

This alliance consists of 10 European private sector plasma collectors, operating 137 plasma collection centers:

biopharma logoEUROPLASMA logoGrifols logoKedplasma United States logoactapharma logoplasma place logoPlasma vita logoProthya logoTakeda logo
unica plasma logo

The EPA’s mission is to promote safe plasma collection practices in the EU with a focus on donor health and donor safety to ensure patients’ access to safe products.

The EPA members currently operate 137 plasma collection centers in four European countries: Germany, Austria, Czech Republic, and Hungary. Last year, EPA members contributed almost 3 million liters of plasma to manufacture lifesaving therapies.

Find a collection center near you

Our goals

Foster plasma collection in Europe
An increasing number of patients across the European Union are diagnosed with life-threatening plasma protein-related disorders, such as Immune Deficiencies, Hereditary Angioedema (HAE), Alpha 1-Antitrypsin Deficiency (AATD), some neurological disorders, or bleeding disorders, such as Hemophilia. Plasma-derived medicinal products (PDMPs) are the primary or, in some cases, the only treatment available for these rare diseases. These developments result in a growing clinical need for PDMPs.
A key element which determines the availability of PDMPs is continuous access to the safe, high-quality starting material, which is human plasma. To meet the growing clinical need of European patients for PDMPs, Europe needs to increase its collection of plasma.To meet this need for increased plasma collection, the EPA advocates for:

  • Establishing dedicated plasma collection (plasmapheresis) programs and coordinated outreach campaigns toward plasma donors in all European Member States

  • Allowing the co-existence of public sector and private sector plasma collection centers

  • Stimulating plasma donations by also allowing compensation of donors for the expenses and inconvenience related to the donation, similar to EU Tissues and Cells Directive (2004/23/EC, article 12.1)

  • Differentiating between whole blood for transfusion and plasma collection for manufacturing of PDMPs, which is currently lacking in many policy frameworks

These suggestions should be addressed in appropriate policy frameworks at the European and national levels.

Safety is priority

Collecting more plasma from healthy donors in Europe and ensuring adequate patient access to care is stringently linked to preserving donor health.

  • Plasma donors are saving lives and EPA members are committed to the health and safety of every person who donates plasma

  • PPTA and EPA support donor health studies

  • Donors are diverse – Given that the profiles of whole blood donors and source plasma donors differ, “one-size-fits-all” policies are not appropriate

  • Monitoring of relevant parameters allows tailoring donation intervals & volume.The EPA supports policy decisions regarding donor safety that are based on scientific rationale and data, and which include input from all stakeholders in a fully transparent process.

Contacts

Mag. Milan Maly, European Plasma Alliance, Chairman

epa@pptaglobal.org

Alexa Wetzel, Director, Source Europe

epa@pptaglobal.org

A man and his child are hugging each other
A boy and girl sibling are holding a paper that says: "Worth a cure"
A young woman and her doctor during the plasma donation process.
A boy is smiling.
A young woman and her doctor during the plasma donation process.
A lady with her girl child are smiling.
A young man during the plasma donation process.
A girl smiles.
< DRAG >

PPTA Europe

This alliance consists of 11 European private sector plasma collectors, operating 137 plasma collection centers:

PPTA France

PPTA France regroupe les laboratoires Kedrion, Grifols et Takeda, spécialisés dans le développement et la production de médicaments dérivés du plasma sanguin et analogues recombinants. L’association a pour mission de contribuer à l’amélioration de la couverture des besoins des patients en protéines thérapeutiques au travers d’un dialogue continu avec les autorités et les agences de santé françaises.


Dans leur ensemble, les entreprises membres de PPTA représentent plus de 50% du marché français des immunoglobulines, en volume. Leurs produits - dont certains n’ont pas d’équivalents - traitent chaque année des dizaines de milliers de patients présentant des maladies rares et graves.

Dans un contexte de difficultés récurrentes en France relatives à la mise à disposition des médicaments dérivés du plasma, l’association invite les pouvoirs publics à réfléchir aux défis de la filière dans leur globalité (approvisionnement en produits finis, conditions d’accès au marché, attractivité de la France…).

PPTA France est affiliée à l’association internationale PPTA (Plasma Protein Therapeutics Association).

Les 4 propositions concrètes de PPTA France pour contribuer à améliorer la couverture des besoins des patients français en médicaments dérivés du plasma.


Pour plus d’informations veuillez contacter Alexa Wetzel, Director, Lead for European Plasma.

Read more

PPTA Deutschland

Die Plasma Protein Therapeutics Association (PPTA) Deutschland ist die Interessenvertretung der privaten Hersteller von plasmatischen Arzneimitteln und deren rekombinanter Analoga. Sie vertritt 5 Mitgliedsunternehmen sowie über 70 Plasmaspendezentren.


Die PPTA setzt ihren Mitgliedsfirmen globale Standards für die Gewährleistung von Qualität und Sicherheit bei der Plasmaspende sowie bei der Verarbeitung von Plasma zu Arzneimitteln, wobei dies sowohl zum Schutz der Plasmaspender als auch der Patienten erfolgt, die auf Arzneimittel aus Plasma angewiesen sind. Die PPTA Deutschland begleitet legislative und politische Initiativen mit Relevanz für seltene Erkrankungen, dem Themenbereich Plasmaspenden und setzt sich für eine angemessene Versorgung von Patienten mit seltenen Erkrankungen ein, die auf Plasma-basierte Arzneimittel angewiesen sind.

Read more
PPTA Deutschland website

Code of ethics

Our code of ethics ensures the ethical conduct and integrity of the Association. Our members pledge to:

Provide the highest quality of therapies, considering the health and safety of users of plasma protein therapies (i.e., patients).
Offer therapies to all patients regardless of race, creed, national origin, or source of illness.
Continue to expand and improve the professional knowledge and therapy quality associated with the supply and use of therapies.
Abide by state, national, and multinational laws and regulations that govern the plasma protein therapies and source plasma collection industries, including antitrust and competition laws.
See full list
A list that represents PPTA's code of ethics.

Join PPTA

Become a member of PPTA! PPTA engages with stakeholders to establish and improve regulations and policies that affect the sector.

By being a member of our industry-leading association, you can work closely with influential partners, enjoy numerous benefits and access useful resources.

Join now
24-hour crisis management assistance
Subscriptions to industry leading briefings, magazine, and reports
Discount for two premier annual industry conferences
Access to legislative and regulatory expertise
Takeda logo
Kedrion logoGrifols logoADMA logoKAMADA logoProthya logoABO plasma logoBiolife logoPrevipharma logounica plasma logo
Takeda logo
Kedrion logoGrifols logoADMA logoKAMADA logoProthya logoABO plasma logoBiolife logoPrevipharma logounica plasma logo

Contact us

If you have any inquiries, get in touch with us by filling out our contact form.

Contact us

Contact us

*please add a valid email
Send now
Thank you for filling out your information! We will review your submission shortly.
Oops! Something went wrong while submitting the form.
< DRAG >